Background: Azithromycin 1% and 1.5% ophthalmic preparations are used widely in clinical practice for the treatment of signs and symptoms of eye diseases. The aim of this study was to render conclusive evidence by comparing the efficacy of azithromycin 1% and 1.5% over tobramycin 0.3% ophthalmic solutions for the treatment of eye diseases in a short duration in terms of bacterial resolution, the cure rate, and resolving clinical sign and symptoms.
Methods: Systematic searches were performed in the electronic database (MEDLINE, Embase, Emcare, CINAHL, Scopus, PubMed, ProQuest, and Web of Science) and other sources. Multicenter randomized controlled trial studies conducted in English were identified and screened. Analysis of individual studies was conducted using the OpenMeta-analyst and Review Manager Version 5.3 software.
Results: Eleven studies were included in the systematic review and meta-analysis. In clinical cure rate, azithromycin 1% and 1.5% eye drops were more effective than tobramycin 0.3% eye drops in short duration dosing (⩽5 days) with a twice-a-day regimen (relative risk = 1.13; 95% confidence interval: 1.008, 1.28), whereas on increased duration (>5 days), azithromycin is almost similarly as effective as tobramycin (relative risk = 1.007; 95% confidence interval: 0.96, 1.05). There was no significant difference in efficacy of bacterial resolution of azithromycin (1%, 1.5%) eye drops compared to tobramycin (0.3%) eye drops (relative risk = 0.99; 95% confidence interval: 0.96, 1.018). Azithromycin eye drops are effective in improving the signs and symptoms of eye disease.
Conclusion: Azithromycin 1% or 1.5% is more effective in the clinical cure rate of eye disease than tobramycin 0.3% eye drops in ⩽5 days of treatment. It is also the best choice of treatment for improving the signs and symptoms of eye disease. So that we recommend clinicians to use azithromycin 1% or 1.5% eye drops.
Systematic Review Registration: PROSPERO 2019 CRD42019139911.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502802 | PMC |
| http://dx.doi.org/10.1177/2050312120958846 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The metabolic pathway of Deg-AZM and investigations into the contribution of drug metabolizing enzymes and drug transporters in the drug interactions of Deg-AZM, a clinical-stage new transgelin agonist.
Front Pharmacol
January 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China.
Introduction: Deglycosylated azithromycin (Deg-AZM), a new transgelin agonist with positive therapeutic effects on slow transit constipation, has been approved for clinical trials in 2024. This work investigated the drug metabolism and transport of Deg-AZM to provide research data for further development of Deg-AZM.
Methods: A combination of UPLC-QTOF-MS was used to obtain metabolite spectra of Deg-AZM in plasma, urine, feces and bile.
Molecular detection of in bovine respiratory disease.
Vet Med (Praha)
December 2024
Department of Internal and Preventive Veterinary Medicine, College of Veterinary Medicine, University of Wasit, Wasit, Iraq.
Bovine respiratory disease (BRD) develops from complex interactions among environmental, host and pathogenic factors. This study aimed to phenotypically identify isolated from cattle with BRD and assess antimicrobial susceptibility and determining the molecular phylogeny of local strains. Between November 2023 and March 2024, nasal swabs were collected from 93 cattle with BRD, before culturing for phenotypic analysis, and performing the polymerase chain reaction (PCR) for molecular characterisation.
View Article and Find Full Text PDFPharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study.
Pharmacogenomics
January 2025
Department of Clinical Pharmacology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Background: Macrolides are widely used antibiotics, but adverse drug reactions (ADRs), particularly in genetically predisposed individuals, can compromise their safety. This study examines the impact of pharmacogenetic markers on macrolide safety in participants with bacterial complications of influenza.
Objective: To evaluate how polymorphisms in genes encoding transporter proteins (ABCB1) and enzymes (CYP3A4, CYP3A5) influence ADR risk during macrolide therapy.
Objectives: To analyze the clinical and biological characteristics and to evaluate the risk factors associated with the mortality of patients with COVID-19 in Commune IV of the District of Bamako.
Methods: The cohort consisted of COVID-19 patients managed from March 2020 to June 2022 at the Bamako Dermatology Hospital and the Pasteur Polyclinic in Commune IV in Bamako. The studied variables were sociodemographic, clinical, and biological.
Evaluating the antibacterial efficacy of bee venom against multidrug-resistant pathogenic bacteria: Escherichia coli, Salmonella typhimurium, and Enterococcus faecalis.
World J Microbiol Biotechnol
January 2025
Microbiology, Botany Department, Faculty of Agriculture, Tanta University, Tanta City, 31527, Egypt.
Bee venom (BV) represents a promising natural alternative to conventional antibiotics, particularly significant given its broad-spectrum antimicrobial activity and potential to address the growing challenge of antimicrobial resistance. The prevalence of antimicrobial-resistant microorganisms (AMR) is a global burden that affects human health and the economies of different countries. As a result, several scientific communities around the world are searching for safe alternatives to antibiotics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!